A

Aileron Therapeutics Inc
NASDAQ:ALRN

Watchlist Manager
Aileron Therapeutics Inc
NASDAQ:ALRN
Watchlist
Price: 1.75 USD -0.57% Market Closed
Market Cap: 37.9m USD
Have any thoughts about
Aileron Therapeutics Inc?
Write Note

Net Margin
Aileron Therapeutics Inc

0%
Current
0%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-29.2m
/
Revenue
0

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Aileron Therapeutics Inc
NASDAQ:ALRN
37.9m USD N/A
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.8B EUR
-14%
Country US
Market Cap 37.9m USD
Net Margin N/A
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 310.3B USD
Net Margin
9%
Country US
Market Cap 141.6B USD
Net Margin
13%
Country US
Market Cap 115.3B USD
Net Margin
0%
Country US
Market Cap 102.4B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 77.3B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 35.8B EUR
Net Margin
-14%
No Stocks Found

Aileron Therapeutics Inc
Glance View

Market Cap
37.9m USD
Industry
Biotechnology

Aileron Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Boston, Massachusetts and currently employs 9 full-time employees. The company went IPO on 2017-06-29. The firm is focused on developing medicines to make chemotherapy safer. ALRN-6924, is its MDM2/MDMX dual inhibitor, which is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the chemoprotective agent in clinical development, which focuses on treating patients with p53-mutated cancers. The company is developing ALRN-6924 to selectively protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced toxicities. The company stabilizes peptides by stapling them with hydrocarbon bonds into their natural alpha-helical conformation. Its platform enables it to chemically stabilize and improve the activity of a range of alpha-helical peptides. ALRN-6924 can pause cell division in cells with wild type (WT), p53, including normal bone marrow cells, and ALRN-6924 has no activity against cancer cells with mutations in p53.

ALRN Intrinsic Value
0.81 USD
Overvaluation 53%
Intrinsic Value
Price
A

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-29.2m
/
Revenue
0
What is the Net Margin of Aileron Therapeutics Inc?

Based on Aileron Therapeutics Inc's most recent financial statements, the company has Net Margin of 0%.